Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

W Winn

Showing results (51-60 of 73) with videos related to

Pageof 8
Sort By:
Arthritis and Rheumatism|August 29, 2009
Novel evidence-based systemic lupus erythematosus responder indexRichard A Furie, Michelle A Petri, Daniel J Wallace, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 17, 2016
A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic LymphohistiocytosisMingce Zhang, Claudia Bracaglia, Giusi Prencipe, et al.
The Journal of Rheumatology|November 5, 2013
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusEllen M Ginzler, Daniel J Wallace, Joan T Merrill, et al.
The Journal of Clinical Investigation|May 30, 2009
Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneityHitoshi Suzuki, Run Fan, Zhixin Zhang, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
Arthritis and Rheumatism|January 26, 2012
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosusWilliam Stohl, Falk Hiepe, Kevin M Latinis, et al.
Arthritis and Rheumatism|August 29, 2009
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusDaniel J Wallace, William Stohl, Richard A Furie, et al.
The Journal of Rheumatology|June 19, 2012
Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trialW Winn Chatham, Daniel J Wallace, William Stohl, et al.
Arthritis and Rheumatism|December 1, 2011
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusRichard Furie, Michelle Petri, Omid Zamani, et al.
Arthritis and Rheumatism|August 31, 2012
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosusKenneth C Kalunian, W Winn Chatham, Elena M Massarotti, et al.
Pageof 8

Showing results (51-60 of 73) with videos related to

Sort By:
Pageof 8
Arthritis and Rheumatism|August 29, 2009
Novel evidence-based systemic lupus erythematosus responder indexRichard A Furie, Michelle A Petri, Daniel J Wallace, et al.
Journal of Immunology (Baltimore, Md. : 1950)|February 17, 2016
A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic LymphohistiocytosisMingce Zhang, Claudia Bracaglia, Giusi Prencipe, et al.
The Journal of Rheumatology|November 5, 2013
Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosusEllen M Ginzler, Daniel J Wallace, Joan T Merrill, et al.
The Journal of Clinical Investigation|May 30, 2009
Aberrantly glycosylated IgA1 in IgA nephropathy patients is recognized by IgG antibodies with restricted heterogeneityHitoshi Suzuki, Run Fan, Zhixin Zhang, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|February 17, 2019
Safety and Efficacy of Belimumab Plus Standard Therapy for Up to Thirteen Years in Patients With Systemic Lupus ErythematosusDaniel J Wallace, Ellen M Ginzler, Joan T Merrill, et al.
Arthritis and Rheumatism|January 26, 2012
Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosusWilliam Stohl, Falk Hiepe, Kevin M Latinis, et al.
Arthritis and Rheumatism|August 29, 2009
A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosusDaniel J Wallace, William Stohl, Richard A Furie, et al.
The Journal of Rheumatology|June 19, 2012
Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trialW Winn Chatham, Daniel J Wallace, William Stohl, et al.
Arthritis and Rheumatism|December 1, 2011
A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosusRichard Furie, Michelle Petri, Omid Zamani, et al.
Arthritis and Rheumatism|August 31, 2012
Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosusKenneth C Kalunian, W Winn Chatham, Elena M Massarotti, et al.
Pageof 8